Login / Signup

Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67 : Are there Patients who are less Likely to Benefit?

Christoph C KurmannAdnan MujanovicEike I PiechowiakTomas DobrockyFelix ZiboldMorin BeyelerJan VynckierDavid SeiffgeThomas R MeinelPasquale MordasiniMarcel ArnoldUrs FischerJan GrallaJohannes Kaesmacher
Published in: Clinical neuroradiology (2022)
Beneficial effect of eTICI 2c/3 over eTICI 2b50/2b67 only decreased in older patients, M2-occlusions and patients with either low or very high NIHSS. Improving eTICI 2b50/2b67 to eTICI 2c/3 in those subgroups may be more often futile.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • single cell